Dr. Arbiser's research focuses on the regulation of angiogenesis and tumorigenesis by signal transduction pathways. Our laboratory has chosen three model systems to study these relationships. The first area is the common vascular birthmarks of children and their malignant counterparts, angiosarcomas. The second application of these studies are benign neoplasms which develop in the autosomal dominant syndrome tuberous sclerosis (TS). The third application of these studies is in the pathogenesis of malignant melanoma. Dr Arbiser has developed the hypothesis that oncogenes disrupt the balance between angiogenesis stimulators and inhibitors.
I have 2 areas of ongoing investigation. One focus is a C-type lectin-family receptor (CD303) expressed uniquely on the surface of human plasmacytoid dendritic cells. Data suggest that this receptor impacts function of these cells in innate and adaptive immunity. We have developed unique biochemical tools to better understand the structure and function of CD303 including identification of natural binding targets whether of self or non-self origin. Specific efforts focus on identifying the specific counter-receptors on these targets and better characterizing the impact of receptor-ligand engagement. A second focus involves deciphering the role of the Bcl-6 interacting transcriptional co-repressor MTA3 and BCL6 in B cell lymphomas, work done in collaboration with Dr. P. Wade at NIEHS, and translating this knowledge into diagnostically useful tools.
Dr. Waller's research focus is in enhancing immune reconstitution after stem cell transplant and developing cell therapy for anti-tumor immunology and in regenerative medicine. His current research activities include pre-clinical and clinical studies focused on the role of donor immune cells in optimizing anti-tumor immunity after allogenic transplantation, and the clinical application of autologous CD34+ cells in improving vascular function and facilitating neo-angiogenesis in patients with peripheral and coronary vascular disease. His NIH-funded basic research lab uses mouse models and performs immunological analyses of clinical samples from patients. He has active translational research activities and serves as a principal investigator on institutional and national cooperative group clinical trials.
My main research interest is the biological role of mRNA transport and local translation in neurons and their dysfunction in neurological diseases. Our emphasis is on the axonal function of the spinal muscular atrophy (SMA) disease protein SMN and the amyotrophic lateral sclerosis (ALS) disease protein TDP-43 in motor neurons. SMA results from reduced levels of the survival of motor neuron (SMN) protein, which has a well characterized function in spliceosomal small nuclear ribonucleoprotein assembly. ALS is characterized by cytoplasmic inclusions containing the RNA-binding protein TDP-43, and mutations in the gene encoding TDP-43 have been directly linked to the development of the disease. Currently, it is not understood how deficiency in proteins with a housekeeping function in RNA metabolism leads to the selective degeneration of motor neurons.
Dr. Robertson received his MD and PhD from Georgetown University. He then completed a general surgery internship at Milton S. Hershey Medical Center at The Pennsylvania State University before an orthopedic surgery research fellowship from Brigham and Women's Hospital and a Harvard combined orthopedic residency from Harvard Medical School. After Harvard, Dr. Robertson went to Johns Hopkins Hospital for radiology residency. He then completed a musculoskeletal radiology fellowship from Mallinckrodt Institute of Radiology at Washington University. Before joining the faculty at Emory University Hospital in 2010 as an Acting Professor of Radiology, Dr. Robertson was an Associate Professor in the Departments of Radiology and Bio-Engineering at the University of Pittsburgh. He was also founding President of the private practice Foundation Radiology Group in Pittsburgh, Pennsylvania.